Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Atara Biotherapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 37 | 32 | −5 |
| Shares | 2.09M | 1.80M | −283.4K (−13.6%) |
| Value | $12.4M | $13.9M | +$1.53M (+12.3%) |
New holders (4)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 42,355 | $327.0K | 0.00% |
| Citadel Advisors LLC | 23,003 | $177.6K | 0.00% |
| Mackenzie Financial Corp | 22,514 | $173.8K | 0.00% |
| Raymond James Financial Inc | 4,021 | $31.0K | 0.00% |
Sold out (9)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Tang Capital Management LLC | 75,196 | $446.7K |
| Susquehanna International Group, LLP | 41,014 | $243.6K |
| Birchview Capital, LP | 22,000 | $130.7K |
| Boston Private Wealth LLC | 421 | $2.50K |
| Russell Investments Group, Ltd. | 368 | $2.19K |
| Lazard Asset Management LLC | 368 | $2.00K |
| Tower Research Capital LLC (TRC) | 185 | $1.10K |
| IFP Advisors, Inc | 180 | $1.07K |
| Barclays PLC | 1 | $6 |